{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"PFS at 20 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"PFS at 36 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"PFS at 60 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Progression-free survival is defined as the interval from the date of initiation of maintenance therapy after salvage ASCT to the earlier of the first documentation of objective disease progression or death from any cause.","groups":[{"description":"Beginning 60 days to 180 (+/- 14) days post ASCT, patients with relapsed multiple myeloma prior to transplant, or undergone previous ASCT, followed by relapse and at least a partial response to salvage therapy will receive maintenance therapy with daratumumab/hyaluronidase-fihj and pomalidomide.\n\nDaratumumab 1800 mg/hyaluronidase-fihj 30,000 units will be given SC weekly for weeks 1-8, followed by every 2 weeks for weeks 9-24, and then every month for weeks 25 until progression.\n\nPomalidomide will be given at 2 mg PO daily from day 1-21 in the 28-day cycle for up to 4 weeks.","id":"OG000","title":"Maintenance Therapy With Daratumumab/Hyaluronidase-fihj/Pomalidomide Post ASCT in MM Patients."}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From the date of initiation of maintenance therapy assessed up to 5 years","title":"Number of Participants That Relapsed With Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Participants"}